Introduction
Dilated cardiomyopathy (DCM) is a heart muscle disorder defined by the presence of a dilated and poorly functioning left ventricle in the absence of systemic hypertension, valve disease, and ischemic heart disease (1) . DCM accounts for 30% to 40% of all heart failure cases in large clinical trials and is the leading cause of heart transplantation (2, 3) .
Ventricular assist devices (VAD) are used as a bridge therapy to heart transplant or as a permanent solution for heart failure. Ongoing refinements in technology have led to improved patient outcomes and device durability, although problems device consisted of 2 circumferential rubber muscles (Fluidic Muscle; Festo) whose ends were fixed to a 50-mm stainless steel bar through 30-mm-long reinforced polyethylene connectors ( Fig. 1A, B ). The device body weight, including rubber muscles, connectors and the stainless steel bar, was 50 g. Characteristics of the rubber muscles have been documented previously (18, 19) . Briefly, the muscle is formed by a pressure-tight rubber hose and is 5 mm in diameter. The driving force is compressed air. Maximal permissible contraction is 25% of the normal length. The device was composed of actuators, pressure sensors (PSE510-M5; SMC), solenoid valves (BV214A-CB0-00-BCNA-CTA; MAC Valves), micro-sequencers (FX1N-40MT, FX2N-16EXL-C; Mitsubishi Electric) and an air compressor.
With approval from the Institute of Animal Experiments of the Hirosaki University Graduate School of Medicine, 6 male crossbred pigs were used in this study. All pigs were treated and cared for in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Japanese Ministry of Education, Culture, Sports, Science and Technology (20) . Six pigs (average weight, 10.8 ± 0.8 kg) underwent pacemaker implantation, followed by delayed loading of a new direct epicardial assist device. Additionally, 6 healthy weight-matched controls (average weight, 22.3 ± 2.3 kg) were used for hemodynamic comparisons.
DCM induction
Treatment pigs were sedated with an intramuscular injection of 30 mg/kg ketamine, followed by an intravenous bolus injection of 0.1 mg/kg midazolam. After intubation with mechanical ventilation, general anesthesia was maintained by intravenous continuous infusion of midazolam (0.1-0.2 mg/ kg/h) and remifentanil hydrochloride (0.25 µg/kg/min). A bipolar tined pacing lead (CapSure Z Novus 5054; Medtronic) was inserted into the left internal jugular vein and positioned in the right ventricular apex. The lead was connected to a pacemaker (Adapta DR; Medtronic), and the pacing system was placed in a subcutaneous pocket. The pacemaker was activated for right ventricular pacing at 170 beats per minute. A 1:1 rate of capture was verified via electrocardiographic recordings and echocardiography. Electrocardiographic recordings were performed frequently during the pacing protocol to ensure continuous capture. After 6 to 8 weeks of active pacing, the pigs were returned to the laboratory to deactivate the pacing and device implantation.
Hemodynamic data measurements
The average weight of DCM models at terminal study was 22.6 ± 2.1 kg. Tracheostomy was performed and a tracheal tube was placed. Anesthesia was maintained with intravenous continuous infusion of midazolam (0.1-0.2 mg/kg/h) and remifentanil hydrochloride (0.25 µg/kg/min). A bolus of vecuronium (0.04 mg/kg) was administered every 20 minutes during the procedure. Intravenous infusion of amiodarone was initiated at 0.5 mg/kg/h. After stabilization of the anesthesia, a multilumened thermodilution catheter was positioned in the pulmonary artery via the right external jugular vein for the measurement of pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP), and central venous pressure (CVP). The left femoral artery was cut down and a PiCCO pressure catheter (Pulsion Medical Systems) was placed intraaortically for hemodynamic measurements. The catheter was connected to its monitoring device (PiCCO2 PC8500US; Pulsion Medical Systems). After the median sternotomy and pericardiotomy were performed, a 4-Fr catheter sheath (Avanti Catheter Sheath Introducers 504-604P; Cordis) was inserted from the apex of the heart directly, was connected to a dual pressure monitor (BSM9510; Nihon Kohden), and was captured at 1,000 Hz using a multi-data acquisition system (NR-500; Keyence) with an analog to digital converter (NR-HA08; Keyence). Recorded left ventricular pressure (LVP) data were analyzed using NR-H7W software (Wave Logger; Keyence). Direct epicardial echocardiography was performed to obtain visual data and the left ventricular ejection fraction (LVEF). The mitral regurgitant fraction was calculated by antegrade and retrograde flow analysis at the aortic annulus and mitral annulus. 
Device characteristics and implantation
A bipolar temporary myocardial pacing lead (Streamline; Medtronic) was placed in the right atrium to capture the autonomic p wave and was connected to a pacemaker programmer (CareLink® 2090; Medtronic). A 90-bpm DDD pacing mode (atrioventricular [AV]-delay of 200 msec) with output voltage of 5V was initiated. A 5V-power voltage was input to the microsequencer, and the sequence program was driven. The microsequencer control of the solenoid valve opening was done through the ladder logic program. The duration of muscle contraction/dilatation and driving pressure was preset to 200-300 milliseconds and 0.6 MPa, respectively. The schematic device system is summarized in Figure 2A .
The circumferential length of hearts at 1 cm below the atrioventricular groove and the midportion between the atrioventricular groove and apex was respectively measured, and an appropriate length (50-55 mm shorter than measured length) of the artificial muscle was tailored. Two muscles were fixed at a stainless bar at both ends through 30-mmlong plastic connectors. Then, a saccular-shape muscle device was loaded from the apex of the heart to just below the atrioventricular groove ( Fig. 2B ). The device itself was fixed at both sides of the clavicle bones using umbilical tape.
Experimental protocol and data analysis
Steady state hemodynamics, specifically heart rate, atrial blood pressure, CVP, PAP, PCWP, LVP, and echocardiographic LVEF with end-diastolic volume and end-systolic volume were recorded with the ventilator temporarily suspended to prevent respiratory artifact. Cardiac output using pulse contour analysis by the PiCCO system was also obtained. Other circulatory parameters, including stroke volume (SV), systemic vascular resistance (SVR), maximum dP/dt, global ejection fraction (GEF), and cardiac power output (CPO), were also obtained. Measured data points were before loading the device, after the assistance with the device, and after inducing ventricular fibrillation by injecting 15% potassium chloride (20 mL) intravenously while assisting. After obtaining all hemodynamic data, the device was turned off, and each study was terminated.
All numerical circulatory data are presented as means ± standard deviations and were assessed using a paired Student's t-test. Statistical analyses were performed using the SPSS statistical software version 20 (IBM), and a p value less than 0.05 was used as an indicator of statistical significance.
Results
All hemodynamic data indicated the successful establishment of DCM pig models by rapid right ventricular pacing. In echocardiographic data, decreased LVEF (25.2 % ± 3.6% vs. 59.0% ± 6.8%), and increased EDV (44.0 ± 12.2 mL vs. 32 
Device feasibility in synchronization
The device worked regularly, coordinating with native heart movement, and resulted in improvements in hemodynamics. No series of ventricular arrhythmias were observed during assistance. Ventricular function significantly improved when receiving synchronous epicardial assistance, with EF increasing from 25.2% ± 3.6% to 47.7% ± 7.8% (p<0.01) and CO increasing from 1.39 ± 0.24 L/min to 1.96 ± 0.46 L/min (ΔCO ranged from 0.29 L/min to 0.9 L/min). EDV appropriately remodeled from 44.0 ± 12.2 mL to 35.0 ± 12.1 mL while SV increased from 14.5 ± 3.3 mL to 20.1 ± 4.3 mL. Left ventricular pressure did not significantly change, while SVR markedly decreased from 4,786 ± 1,022 dynes•sec•cm -5 to 3,960 ± 844 dynes•sec•cm -5 (p = 0.09), which corresponded with an improvement in output. Heart rate did not significantly change after the assistance (96.8 ± 7.3 bpm before the assistance, 97.1 ± 6.7 bpm after the assistance). Hemodynamic variables are summarized in Table I . Configuration of left ventricular pressure demonstrated an early notch in the systolic phase, indicating contraction support by the epicardial assist device (Fig. 3A, B) .
The steady state of DCM models in both the unassisted and assisted condition demonstrated evidence of mitral regurgitation. However, no difference was observed in the mitral regurgitant fraction between the two conditions (13.6% ± 4.2% vs. 15.2% ± 5.1%, p = 0.58)
Mandatory epicardial support in ventricular fibrillation
After inducing ventricular fibrillation, mandatory device activation was initiated. (Fig. 4A, B) . Heart rate was set ranging from 90 bpm to 120 bpm by modulating the pacemaker programmer. After steady state was obtained, each parameter was measured. CO could still be measured with an average value of 1.33 ± 0.28 L/min. SV was 13.0 ± 4.9 mL, and maximum dP/dT was 297 ± 76 mmHg/s. Average peak systolic left ventricular pressure (depicted in Fig. 3C ) and LVEF was 73.1 ± 22.1 mmHg and 28.1% ± 3.2%, respectively. Systolic and diastolic PAP, PCWP, and CVP were all elevated with an average value of 40.4 ± 9.7 mmHg, 26.4 ± 9.3 mmHg, 22.6 ± 7.2 mmHg, and 21.5 ± 3.4 mmHg, respectively. These data indicated biventricular insufficiency, although dilation of pupils and gasping respiration were not evident during the support. No ventricular perforation or bleeding was observed.
Discussion
This study demonstrated the efficacy of a circumferential epicardial assist device in DCM pig models. Six young pigs underwent DCM induction by a relatively low right ventricular pacing rate of 170 bpm for 6 to 8 weeks, which resulted in the development of increased EDV size and low EF and CO, indicating successful establishment of DCM models. Previous studies showed the development of tachycardia-induced heart failure in response to 220 to 240 bpm for 1 to 3 weeks in pigs weighing 25 to 45 kg (21) (22) (23) (24) . We implanted pacemakers in 6 pigs (weight, 10-12 kg) in order to get smaller DCM models that approximate young children. Lionetti et al induced heart failure in mature mini-pigs by a relatively low pacing rate of 180 bpm, (25) and Paslawska et al induced a cardiomyopathy model by chronic pacing of 170 bpm for 4 to 28 weeks in adult pigs weighing 70 to 74 kg (26) . These studies demonstrated a 47% to 67% decrease in EF when compared with controls, which corresponds to the data from our DCM model.
The positive hemodynamic effects of this device were represented by increasing CO, SV and LVEF with moderate approximation of EDV. EF increased from 25.2% ± 3.6% to 47.7% ± 7.8% after the assistance. It is true that this result should be carefully interpreted, because this was not a double-blind study and could be subject to bias. With regard to objective data, CO increased from 1.39 ± 0.24 L/min to 1.96 ± 0.46 L/ min after the assistance, and its increment ranged from 0.29 to 0.9 L/min. This increment represents a wide range and may not be truly satisfactory, because CO after assistance did not reach the level of that in control pigs (3.14 ± 0.46 L/min).
This prototype device currently has some problems in its design. For example, it is difficult to determine the appropriate length of artificial muscle in each heart. If the muscle length is too long, hemodynamic assistance will become less effective. If the muscle length is too short, it might cause diastolic dysfunction and ventricular arrhythmias, resulting in further deterioration of the hemodynamic state. It is essential to determine the appropriate length of muscles in order to obtain maximum hemodynamic support. We need to invent a new device design that enables us to adjust muscle length flexibly and easily. As for device fitting, mesh fixation is likely to be effective, so as not to slip out from the ventricles.
Positioning might also be a key to successful assistance, because too high positioning near the atrioventricular groove may cause mitral regurgitation, resulting in inefficient blood flow towards the left ventricular outflow tract. The pneumatic muscle itself needs to gain more flexibility and elasticity so as to fit the heart surface in a gentle fashion. Computational fluid dynamics are valuable methods of visualizing left ventricular geometry and material properties (27) (28) (29) (30) . These tools will be essential for optimization of the device and ventricular functioning going forward. Cardiac magnetic resonance imaging is a novel approach for visualizing dynamic flow (30, 31) , which can be utilized to analyze the therapeutic efficacy of this device, as it is technically possible to make the device completely nonferromagnetic.
In synchronizing the native heart, the mechanism of supporting the heart by this device is composed of 2 different factors: extrinsic pumping action of the device contributing to the systolic ejection, and augmentation of autonomic contraction by accelerating wall movement. Contracting the device in the end-systolic phase (as in accelerating pendulum swings) leads to an increase in effective ventricular output. Therefore, it is essential to precisely control the contraction timing of the device. This was a preliminary study, and we fixed primarily the AV delay and contractile duration at 200 milliseconds. AV delay can be modulated by pacemaker programming, and contractile duration can be modulated by the ladder logic program of the microsequencer. Investigators previously studied an in vitro study of this artificial muscle device (19) . In that study, the muscle could contract in 100 milliseconds or longer. Analysis of contraction timing on each cardiac cycles will be performed in future studies.
When ventricular fibrillation was induced, autonomic contractility was lost, and the device worked mandatorily. Systemic CO was maintained at 1.33 ± 0.28 L/min, LVP was maintained at 73.1 ± 22.1/14.7 ± 3.7 mmHg, and systemic pressure was maintained at 74.5 ± 21.7/58.0 ± 21.5 mmHg. There was no sign of brainstem death, and systemic organ function was likely to be maintained. Global biventricular support was achieved without atrial movements. However, elevation of PAP and PCWP were observed; thus, it is likely to be difficult to maintain whole body circulation in the chronic phase. The artificial muscle has a property of 25% contraction of nominal length in the longitudinal direction, according to the manufacturer. This means an ejection fraction of approximately 44% can theoretically be maintained if the device forms a fully covered jacket model by increasing the number of artificial muscles and by filling the interspaces of the present prototype model.
There are other ventricular support devices for direct epicardial assistance. The CorCap Cardiac Support Device (Acorn Cardiovascular) (32) (33) (34) , and the HeartNet Implant (Paracor Medical) have advanced to clinical trials (35, 36) . Both studies demonstrated improvements in end-diastolic and end-systolic volumes of the heart. These 2 devices are passive support devices that provide a restraint effect via sustained transmural myocardial pressure. McGarvey et al reported a novel device for active epicardial ventricular support in ischemic cardiomyopathy (30) . This device utilizes a rubber inflatable bladder that is positioned and fixed at the dyskinetic infarcted area. Use of this device resulted in improvement in hemodynamics, including EF, which increased from 26.0% ± 4.8% to 37.3% ± 4.5% after the assistance. Its concept is similar to our device, although that device is specialized for ischemic cardiomyopathy and represents focal support rather than global support and therefore might not be applicable to the global ventricular impairment of DCM.
DCM is commonly accompanied by right ventricular dysfunction (37) . The pathophysiology of heart failure is likely to be different in children than in adults. (12) Isolated left ventricular dysfunction is rare in children, in whom the need for circulatory support is often due to a combination of right ventricular failure, hypoxemia and pulmonary hypertension. The full jacket device presented in this report might be able to support both the left and the right ventricles, because the artificial muscles contract in a concentric fashion, and therefore, its force of contractility may conduct equally to both ventricles. This topic should be assessed in future studies.
To advance this device to clinical use, frictional force against the epicardial surface and heat production by prolonged continuous driving may have to be resolved. Too much frictional force may result in ventricular perforation and bleeding, and the heat may cause protein degeneration, leading to further ventricular deterioration. There was no perforation or bleeding observed in this acute preliminary study. Chronic device placement will be the focus of future studies.
In conclusion, a circumferential direct epicardial assist device resulted in improvement in hemodynamic data in a young DCM model in this preliminary study. Although further work is needed to analyze its characteristics and there is still a need for improvements in device components, this direct cardiac assistance device may be a good alternative to recent heart failure device therapies for this subset of pathology.
